Advances in treating acute myeloid leukemia.
Acute myeloid leukemia (AML) arises within the bone marrow from a malignant hematopoietic progenitor cell. Though AML is still often fatal, cure rates overall continue to improve incrementally yet steadily, primarily for two reasons: first, insights into the pathogenesis of AML over the last several decades have led to the development of a relatively sophisticated classification scheme that allows more nuanced risk stratification to guide treatment choices; second, improvements in stem cell transplantation have allowed many more patients to take advantage of this highly effective therapeutic technique. Improvements in overall survival for patients with AML are expected to continue rising because of the anticipated introduction of targeted therapies into this treatment platform.
J Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 401 N. Broadway, Baltimore, MD 21231 USA.
Margaret M
MM
Showel
J Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 401 N. Broadway, Baltimore, MD 21231 USA.
Mark
M
Levis